Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.

Greenall SA, McKenzie M, Seminova E, Dolezal O, Pearce L, Bentley J, Kuchibhotla M, Chen SC, McDonald KL, Kornblum H, Endersby R, Adams TE, Johns TG.

Neuro Oncol. 2019 Apr 19. pii: noz073. doi: 10.1093/neuonc/noz073. [Epub ahead of print]

PMID:
31002307
2.

Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.

Donoghue JF, Kerr LT, Alexander NW, Greenall SA, Longano AB, Gottardo NG, Wang R, Tabar V, Adams TE, Mischel PS, Johns TG.

Cancers (Basel). 2018 Jul 25;10(8). pii: E243. doi: 10.3390/cancers10080243.

3.

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3.

Greenall SA, Donoghue J, Johns TG, Adams TE.

Transl Oncol. 2018 Aug;11(4):971-978. doi: 10.1016/j.tranon.2018.05.011. Epub 2018 Jun 22.

4.

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.

Endersby R, Whitehouse J, Hii H, Greenall SA, Johns TG, Gottardo NG.

Neoplasia. 2018 May;20(5):432-442. doi: 10.1016/j.neo.2018.02.004. Epub 2018 Mar 22.

5.

EGFRvIII: the promiscuous mutation.

Greenall SA, Johns TG.

Cell Death Discov. 2016 Jul 4;2:16049. doi: 10.1038/cddiscovery.2016.49. eCollection 2016. No abstract available.

6.

Incomplete target neutralization by the anti-cancer antibody rilotumumab.

Greenall SA, Adams TE, Johns TG.

MAbs. 2016;8(2):246-52. doi: 10.1080/19420862.2015.1122149.

7.

Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.

Nilsson UW, Johns TG, Wilmann T, Kaitu'u-Lino T, Whitehead C, Dimitriadis E, Menkhorst E, Saglam B, Gao Y, Greenall SA, Horne AW, Tong S.

Obstet Gynecol. 2013 Oct;122(4):737-44. doi: 10.1097/AOG.0b013e3182a1ba56.

PMID:
24084529
8.

Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer.

Greenall SA, Bentley JD, Pearce LA, Scoble JA, Sparrow LG, Bartone NA, Xiao X, Baxter RC, Cosgrove LJ, Adams TE.

J Biol Chem. 2013 Jan 4;288(1):59-68. doi: 10.1074/jbc.M112.432013. Epub 2012 Nov 19.

9.

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG.

PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12.

10.

Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.

Ymer SI, Greenall SA, Cvrljevic A, Cao DX, Donoghue JF, Epa VC, Scott AM, Adams TE, Johns TG.

Cancers (Basel). 2011 Apr 18;3(2):2032-49. doi: 10.3390/cancers3022032.

11.

Antibody fragments, expressed by a fowl adenovirus vector, are able to neutralize infectious bursal disease virus.

Greenall SA, Tyack SG, Johnson MA, Sapats SI.

Avian Pathol. 2010 Oct;39(5):339-48. doi: 10.1080/03079457.2010.507239.

PMID:
20954010

Supplemental Content

Loading ...
Support Center